# OnCo record paper-spigel-pacific-five-year-survival-jco-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-spigel-pacific-five-year-survival-jco-2022" ;
schema:name "Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer"@en ;
schema:description "Five years after the PACIFIC trial, 42.9 percent of patients given a year of immunotherapy after chemoradiotherapy were still alive, against 33.4 percent of those given placebo. A third of them had never relapsed."@en ;
schema:url ;
schema:dateModified "2026-09-25"^^xsd:date ;
schema:citation , , ;
onco:tag "lung-evidence" ;
schema:sameAs ;
schema:datePublished "2022"^^xsd:gYear ;
schema:author "Spigel DR, Faivre-Finn C, Gray JE, et al." ;
onco:related , , ;
onco:cancers , , ;
onco:sections , ;
onco:technologies , , ;
onco:targets ;
onco:drugs ;
onco:companies ;
onco:pathways ;
onco:terms , ;
onco:trials ;
onco:people , ;
onco:bottlenecks , ;
onco:journals .